芦可替尼治疗骨髓纤维化患者的第二原发恶性肿瘤
男性及芦可替尼起始时血小板>400×10^9/L与风险增高相关,建议加强皮肤监测和肿瘤筛查。
要点
- 男性及血小板>400×10^9/L是第二原发恶性肿瘤的独立危险因素。
核心结论
- 芦可替尼治疗的骨髓纤维化患者中第二原发恶性肿瘤并不罕见,以非黑色素瘤皮肤癌为主。
- 未记录到侵袭性淋巴瘤,但建议所有患者进行积极皮肤监测。
研究设计与样本
- 真实世界背景下分析700例接受芦可替尼治疗的骨髓纤维化患者。
临床怎么用
- 对所有接受芦可替尼治疗的骨髓纤维化患者推荐积极皮肤监测。
- 延长羟基脲治疗后尤其应加强皮肤监测。
- 血小板增多和动脉血栓史,尤其男性,应触发肿瘤筛查。
局限性
- 真实世界研究设计可能存在选择偏倚和回顾性数据收集局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with the occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs). We analyzed the incidence, risk factors and outcome of SPMs in 700 MF patients treated with RUX in a real-world context. Median follow-up from starting RUX was 2·9 years. Overall, 80 (11·4%) patients developed 87 SPMs after RUX start. NMSCs were the most common SPMs (50·6% of the cases). Multivariate analysis demonstrated that male sex [hazard ratio (HR): 2·37, 95% confidence interval (95%CI): 1·22-4·60, P = 0·01] and thrombocytosis> 400 × 109 /l at RUX start (HR:1·98, 95%CI: 1·10-4·60, P = 0·02) were associated with increased risk for SPMs. Risk factors for NMSC alone were male sex (HR: 3·14, 95%CI: 1·24-7·92, P = 0·02) and duration of hydroxycarbamide and RUX therapy > 5 years (HR: 3·20, 95%CI: 1·17-8·75, P = 0·02 and HR: 2·93, 95%CI: 1·39-6·17, P = 0·005 respectively). In SPMs excluding NMSCs, male sex (HR: 2·41, 95%CI: 1·11-5·25, P = 0·03), platelet > 400 × 109 /l (HR: 3·30, 95%CI: 1·67-6·50, P = 0·001) and previous arterial thromboses (HR: 3·47, 95%CI: 1·48-8·14, P = 0·004) were shown to be associated with higher risk of SPMs. While it is reassuring that no aggressive lymphoma was documented, active skin surveillance is recommended in all patients and particularly after prolonged hydroxycaramide therapy; oncological screening should be triggered by thrombocytosis and arterial thrombosis, particularly in males.
引用
- Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2020. PMID: 33222197. doi:10.1111/bjh.17192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。